Literature DB >> 16861907

Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein.

Chang Soo Hong1, Tohru Yamada, Wataru Hashimoto, Arsenio M Fialho, Tapas K Das Gupta, Ananda M Chakrabarty.   

Abstract

Azurin is a periplasmic 128 amino acid protein in Pseudomonas aeruginosa, termed Paz, which has been shown to enter preferentially and induce apoptosis in cancer cells such as human melanoma or breast cancer. Its effectiveness against brain tumors such as glioblastomas has not been studied. The meningitis-causing bacterium Neisseria meningitidis also harbors an azurin-like protein. Unlike all other known azurins, Neisserial azurin, termed Laz, is surface-exposed and has in its N-terminal region a 39 amino acid epitope called H.8. Upstream of this H.8 moiety is a lipobox that results in the truncation of the protein at the N-terminal cysteine residue with modification by a lipid group. No function of Laz is known. We demonstrate that while Paz is deficient in entering glioblastoma cells and exhibits low cytotoxicity, Laz is much more proficient in entering glioblastoma cells and shows a higher level of cytotoxicity. When the Neisserial H.8 moiety containing the lipobox is fused in frame with Paz either in its N-terminal (H.8-Paz) or in its C-terminal (Paz-H.8), both had high cytotoxicity for glioblastoma cells and a higher level of internalization. When expressed in E. coli, H.8-Paz was much more exposed on the surface than Paz-H.8. The replacement of the Laz N-terminal cysteine residue involved in acylation with an alanine residue abolished the surface display, but had no effect on cytotoxicity or entry in glioblastoma cells, suggesting a role of the H.8 moiety, but not its lipidation, in disrupting the entry barrier in brain tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861907     DOI: 10.4161/cc.5.15.2991

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  9 in total

1.  Azurin-like protein blocks invasion of Toxoplasma gondii through potential interactions with parasite surface antigen SAG1.

Authors:  Arunasalam Naguleswaran; Arsenio M Fialho; Anita Chaudhari; Chang Soo Hong; Ananda M Chakrabarty; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 2.  Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.

Authors:  Meng Gao; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

3.  Bioengineered bugs, drugs and contentious issues in patenting.

Authors:  Ananda M Chakrabarty
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

Review 4.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

5.  Structural studies on Laz, a promiscuous anticancer Neisserial protein.

Authors:  Wataru Hashimoto; Akihito Ochiai; Chang Soo Hong; Kousaku Murata; Ananda M Chakrabarty
Journal:  Bioengineered       Date:  2015-02-25       Impact factor: 3.269

6.  A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Authors:  Greg S Gorman; Lori U Coward; Lea Freeman; Pat E Noker; Craig W Beattie; Lee Jia
Journal:  J Pharm Biomed Anal       Date:  2010-06-30       Impact factor: 3.935

7.  Glioblastoma multiforme: novel therapeutic approaches.

Authors:  Arsenio M Fialho; Prabhakar Salunkhe; Sunil Manna; Sidharth Mahali; Ananda M Chakrabarty
Journal:  ISRN Neurol       Date:  2012-02-08

Review 8.  How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Authors:  R Gasparini; D Panatto; N L Bragazzi; P L Lai; A Bechini; M Levi; P Durando; D Amicizia
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

9.  Bacterial Carriers for Glioblastoma Therapy.

Authors:  Nalini Mehta; Johnathan G Lyon; Ketki Patil; Nassir Mokarram; Christine Kim; Ravi V Bellamkonda
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.